Pediatric rheumatology

New epidemiological characteristics of childhood IgA vasculitis in the post-COVID-19 era: a single-center retrospective cohort study

Pediatr Rheumatol Online JPublished Retrospective cohort study

Authors' conclusion

In the post-COVID-19 era, childhood IgAV presents with new clinical characteristics, marked by an increased overall disease burden and a shift towards more severe clinical phenotypes.

Study context

Population
Children hospitalized with IgA vasculitis (IgAV), single centre
Exposure
Post-COVID-19 era vs Pre-COVID-19
Methodological detailssingle-center, time-series models, multivariate logistic regression
  • Single-center
  • Time-series models
  • Multivariate logistic regression

Main finding

As reported in the abstract

  • Disease burden intensified in Post-COVID-19 era: hospitalization duration, costs and proportion of IgAV admissions surged; observed crude hospitalization rate significantly exceeded model predictions
  • Among newly-diagnosed cases, renal subtype proportion increased significantly and cutaneous-only form decreased
  • Post-COVID-19: significant alterations in humoral immunity and complement profiles, increased Mycoplasma pneumoniae infection

Observational data: associations, not effects.

Further findings

Relapse at 6-month follow-up (newly-diagnosed non-nephritic patients)

No significant difference in relapse rates between cohorts

Progression to IgA vasculitis nephritis (IgAVN) at 6-month follow-up

Progression rate to nephritis significantly elevated in Post-COVID-19 group

Independent predictors of IgAVN

Duration of rash the sole consistent independent predictor across both periods

Original publication

New epidemiological characteristics of childhood IgA vasculitis in the post-COVID-19 era: a single-center retrospective cohort study. Pediatr Rheumatol Online J. Published 19 May 2026. doi:10.1186/s12969-026-01229-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.